Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series.
Li JJ et al.
Pathology, 2026
KRAS and MET Co-Mutation in One Lesion and EGFR Mutation in Another Lesion of Early-Stage Synchronous Multiple Lung Adenocarcinomas: A Case Report.
Ito T et al.
The Tohoku Journal of Experimental Medicine, 2025
The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study.
Yan S et al.
Translational Lung Cancer Research, 2025
Genomic Landscape of NSCLC in the Republic of Ireland.
Keogh RJ et al.
Jto Clinical and Research Reports, 2024
PROMER technology: A new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity.
Nam H et al.
Biology Methods & Protocols, 2024
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.
Tóth LJ et al.
Pathology Oncology Research : Por, 2024
Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer.
De Saint Basile H et al.
Exploration of Targeted Anti-tumor Therapy, 2024
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications.
Craig SG et al.
Molecular Oncology, 2021
Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts.
Rosen JC et al.
Translational Oncology, 2021
Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience.
Burns EA et al.
Journal of Thoracic Disease, 2021
Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).
Mascarenhas E et al.
Thoracic Cancer, 2021
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH et al.
Translational Lung Cancer Research, 2020
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A et al.
Diagnostic Pathology, 2019
KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.
Naidoo J et al.
Advances in Experimental Medicine and Biology, 2016
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.
Dhanasekaran SM et al.
Nature Communications, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
Said R et al.
Oncotarget, 2014
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
Stella GM et al.
Journal of Cancer Research and Clinical Oncology, 2013
Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping.
Beau-Faller M et al.
British Journal of Cancer, 2009